BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26650066)

  • 21. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
    Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
    Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.
    Kratzsch T; Kuhn SA; Joedicke A; Hanisch UK; Vajkoczy P; Hoffmann J; Fichtner I
    J Cancer Res Clin Oncol; 2018 May; 144(5):809-819. PubMed ID: 29427211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma.
    Liu X; Chen X; Shi L; Shan Q; Cao Q; Yue C; Li H; Li S; Wang J; Gao S; Niu M; Yu R
    J Exp Clin Cancer Res; 2019 May; 38(1):219. PubMed ID: 31122294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect.
    Szentirmai O; Baker CH; Lin N; Szucs S; Takahashi M; Kiryu S; Kung AL; Mulligan RC; Carter BS
    Neurosurgery; 2006 Feb; 58(2):365-72; discussion 365-72. PubMed ID: 16462491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.
    Gravina GL; Mancini A; Mattei C; Vitale F; Marampon F; Colapietro A; Rossi G; Ventura L; Vetuschi A; Di Cesare E; Fox JA; Festuccia C
    Oncotarget; 2017 May; 8(18):29865-29886. PubMed ID: 28415741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
    Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
    PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells.
    De Robertis A; Valensin S; Rossi M; Tunici P; Verani M; De Rosa A; Giordano C; Varrone M; Nencini A; Pratelli C; Benicchi T; Bakker A; Hill J; Sangthongpitag K; Pendharkar V; Liu B; Ng FM; Then SW; Jing Tai S; Cheong SM; He X; Caricasole A; Salerno M
    Mol Cancer Ther; 2013 Jul; 12(7):1180-9. PubMed ID: 23619303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.
    Candolfi M; Curtin JF; Nichols WS; Muhammad AG; King GD; Pluhar GE; McNiel EA; Ohlfest JR; Freese AB; Moore PF; Lerner J; Lowenstein PR; Castro MG
    J Neurooncol; 2007 Nov; 85(2):133-48. PubMed ID: 17874037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
    Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An orthotopic glioblastoma animal model suitable for high-throughput screenings.
    Pudelko L; Edwards S; Balan M; Nyqvist D; Al-Saadi J; Dittmer J; Almlöf I; Helleday T; Bräutigam L
    Neuro Oncol; 2018 Oct; 20(11):1475-1484. PubMed ID: 29750281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.
    Marrero L; Wyczechowska D; Musto AE; Wilk A; Vashistha H; Zapata A; Walker C; Velasco-Gonzalez C; Parsons C; Wieland S; Levitt D; Reiss K; Prakash O
    Neoplasia; 2014 Oct; 16(10):874-82. PubMed ID: 25379024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.
    Grogan PT; Sarkaria JN; Timmermann BN; Cohen MS
    Invest New Drugs; 2014 Aug; 32(4):604-17. PubMed ID: 24718901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
    Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
    Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase.
    Wang SD; Rath P; Lal B; Richard JP; Li Y; Goodwin CR; Laterra J; Xia S
    Oncogene; 2012 Dec; 31(50):5132-43. PubMed ID: 22310282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bisdemethoxycurcumin Induces Cell Apoptosis and Inhibits Human Brain Glioblastoma GBM 8401/
    Hsia TC; Peng SF; Chueh FS; Lu KW; Yang JL; Huang AC; Hsu FT; Wu RS
    Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
    Baskin R; Park SO; Keserű GM; Bisht KS; Wamsley HL; Sayeski PP
    PLoS One; 2014; 9(8):e105568. PubMed ID: 25162558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature.
    Kristoffersen K; Nedergaard MK; Villingshøj M; Borup R; Broholm H; Kjær A; Poulsen HS; Stockhausen MT
    Cancer Biol Ther; 2014 Jul; 15(7):862-77. PubMed ID: 24755988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition.
    Yang Z; Garcia A; Xu S; Powell DR; Vertino PM; Singh S; Marcus AI
    PLoS One; 2013; 8(9):e75069. PubMed ID: 24069380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease.
    Radaelli E; Ceruti R; Patton V; Russo M; Degrassi A; Croci V; Caprera F; Stortini G; Scanziani E; Pesenti E; Alzani R
    Histol Histopathol; 2009 Jul; 24(7):879-91. PubMed ID: 19475534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
    Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
    Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.